A Phase 3 interventional study of Cariprazine and Placebo in Schizophrenia, sponsored by AbbVie. Terminated at 97 sites in 11 countries. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2022-04-11.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing cariprazine in Schizophrenia — 4 open to participants now, 4 under way, 2 of them phase 3. cariprazine · Schizophrenia.
Among the 23 studies testing cariprazine in Schizophrenia, this one is the 5th largest by enrollment, is the only one that started in 2018, is one of 8 in phase 3, and was the 15th registered.
3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.
Browse Schizophrenia studies →4 of the 23 studies testing cariprazine in Schizophrenia are open now, in 10 countries. Recruiting first, the newest first:
Mapi Pharma Ltd. · Sites in India, Israel
Ages 18–64
Gedeon Richter Plc. · Sites in United States, Bulgaria, Colombia and 5 more countries
Ages 13–17
New York State Psychiatric Institute
Ages 18–55
Bostal Drug Delivery Co., Ltd
Ages 18–65
By country, each count listing its studies:
cariprazine: first FDA approval 2015 (VRAYLAR), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 11 · Phase 3 14
First in 2006; this study’s year is marked. 1 started in 2018.
This study's enrollment of 587 is above the median of 71 across 2,947 interventional studies indexed under Schizophrenia.
Median enrollment 129 across the 23 interventional studies. Of the 18 that completed or were terminated, 14 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 23 have an industry lead sponsor. The 10 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
27 studies in Schizophrenia by AbbVie: 1 open now, 1 under way, none of them phase 3. Of 26 finished, 11 (42%) have results posted.
Among the 27 studies in Schizophrenia by AbbVie, this one is the 6th largest by enrollment, is the only one that started in 2018, is one of 8 in phase 3, and was the 17th registered.
AbbVie’s Schizophrenia studies by the year they started, since 2004.
3 of the studies testing cariprazine in Schizophrenia that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03817502Phase 3Gedeon Richter Plc.Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia | 2026-12-15 |
| NCT07722728Phase 3Bostal Drug Delivery Co., LtdA Study to Investigate Pharmacokinetics, Safety, and Tolerability of B2227 Extended-Release Injectable Suspension and Vraylar® in Participants With Schizophrenia | 2027-08 |
| NCT07185815Mapi Pharma Ltd.Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine | 2026-12-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 23 studies testing cariprazine in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 27 in Schizophrenia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cariprazine 1.5 mg capsules orally once daily at Week 1, titrated to 3.0 mg capsules orally once daily at Week 2 and then titrated to 4.5 mg orally once daily from Week 3 through Week 18 in the Open-label Treatment Period.
Drug: Cariprazine
Cariprazine placebo-matching capsules orally once daily from Week 19 through Week 44 in Double-blind Treatment Period.
Drug: Placebo
Cariprazine 3.0 mg capsules orally once daily from Week 19 through Week 44 in Double-blind Treatment Period.
Drug: Cariprazine
Cariprazine 4.5 mg capsules orally once daily from Week 19 through Week 44 in Double-blind Treatment Period.
Drug: Cariprazine
Cariprazine capsules, oral administration, once daily.
Matching placebo capsules, oral administration, once daily.
Time to First Relapse During Double-blind Treatment Period
Time to Relapse is the number of days from randomization to first relapse. Relapse is defined as any 1 of the following: * Increase in Positive and Negative Syndrome Scale(PANSS) by ≥30% for participants who had total score of ≥50 at randomization or ≥10-point increased score with total score \<50 at randomization \[PANSS=30 questions where 1=absence of symptoms to 7=extremely severe symptom;total score=30 to 210;higher score more severe symptoms\] * Increase in Clinical Global Impression-Severity (CGI-S) score by 2 or more points \[1=normal to 7=among most extremely ill\] * Score of \>4 on 1 or more of 7 PANSS items:P1-delusions,P2-conceptual disorganization,P3-hallucinatory behavior,P6-suspiciousness,P7-hostility,G8-uncooperativeness,G14-poor impulse control * Deliberate self-injury * Initiation of treatment with mood stabilizer,antidepressant,antipsychotics or benzodiazepine that exceeds specified allowance * Psychiatric hospitalization * Exacerbation of psychiatric illness
Time frame: Randomization (Week 18) to End of Treatment (Week 44)
| Milestone | Cariprazine 4.5 mg/Day (Open-label Treatment Period) | Placebo (Double-blind Treatment Period) | Cariprazine 3.0 mg/Day (Double-blind Treatment Period) | Cariprazine 4.5 mg/Day (Double-blind Treatment Period) |
|---|---|---|---|---|
| Started | 587 | 0 | 0 | 0 |
| Completed | 162 | 0 | 0 | 0 |
| Not completed | 425 | 0 | 0 | 0 |
| Withdrew: Adverse event | 39 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 14 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 85 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 51 | 0 | 0 | 0 |
| Withdrew: Death | 1 | 0 | 0 | 0 |
| Withdrew: Protocol deviation | 5 | 0 | 0 | 0 |
| Withdrew: Non-compliance with study drug | 23 | 0 | 0 | 0 |
| Withdrew: Study terminated by the sponsor | 90 | 0 | 0 | 0 |
| Withdrew: Reason not specified | 13 | 0 | 0 | 0 |
| Withdrew: Failure to meet randomization criteria | 104 | 0 | 0 | 0 |
| Milestone | Cariprazine 4.5 mg/Day (Open-label Treatment Period) | Placebo (Double-blind Treatment Period) | Cariprazine 3.0 mg/Day (Double-blind Treatment Period) | Cariprazine 4.5 mg/Day (Double-blind Treatment Period) |
|---|---|---|---|---|
| Started | 0 | 54 | 49 | 56 |
| Safety population | 0 | 53 | 49 | 54 |
| Completed | 0 | 14 | 16 | 21 |
| Not completed | 0 | 40 | 33 | 35 |
| Withdrew: Number of participants with relapse event | 0 | 15 | 9 | 8 |
| Withdrew: Adverse event | 0 | 2 | 0 | 4 |
| Withdrew: Withdrawal by subject | 0 | 4 | 2 | 3 |
| Withdrew: Lost to follow-up | 0 | 5 | 4 | 1 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 1 |
| Withdrew: Protocol deviation | 0 | 3 | 2 | 5 |
| Withdrew: Non-compliance with study drug | 0 | 1 | 2 | 0 |
| Withdrew: Study terminated by sponsor | 0 | 9 | 11 | 13 |
| Withdrew: Reason not specified | 0 | 1 | 3 | 0 |
Time to Relapse is the number of days from randomization to first relapse. Relapse is defined as any 1 of the following: * Increase in Positive and Negative Syndrome Scale(PANSS) by ≥30% for participants who had total score of ≥50 at randomization or ≥10-point increased score with total score \<50 at randomization \[PANSS=30 questions where 1=absence of symptoms to 7=extremely severe symptom;total score=30 to 210;higher score more severe symptoms\] * Increase in Clinical Global Impression-Severity (CGI-S) score by 2 or more points \[1=normal to 7=among most extremely ill\] * Score of \>4 on 1 or more of 7 PANSS items:P1-delusions,P2-conceptual disorganization,P3-hallucinatory behavior,P6-suspiciousness,P7-hostility,G8-uncooperativeness,G14-poor impulse control * Deliberate self-injury * Initiation of treatment with mood stabilizer,antidepressant,antipsychotics or benzodiazepine that exceeds specified allowance * Psychiatric hospitalization * Exacerbation of psychiatric illness
| days | Placebo (Double-blind Treatment Period) | Cariprazine 3.0 mg/Day (Double-blind Treatment Period) | Cariprazine 4.5 mg/Day (Double-blind Treatment Period) |
|---|---|---|---|
| Time to First Relapse During Double-blind Treatment Period | NA (183.0 to NA) | NA (184.0 to NA) | NA (NA to NA) |
Collected over First dose to last dose + 30 days in the Open-label Treatment Period (Up to 23 weeks); First dose to last dose + 30 days in the Double-blind Treatment Period (Up to 35 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cariprazine 4.5 mg/Day (Open-label Treatment Period) | 1/587 (0.2%) | 20/587 (3.4%) | 83/587 (14.1%) |
| Cariprazine 4.5 mg/Day (Open-label Safety Follow-up) | 0/273 (0%) | 7/273 (2.6%) | 0/273 (0%) |
| Placebo (Double-blind Treatment Period) | 0/54 (0%) | 5/53 (9.4%) | 5/53 (9.4%) |
| Cariprazine 3.0 mg/Day (Double-blind Treatment Period) | 0/49 (0%) | 0/49 (0%) | 9/49 (18.4%) |
| Cariprazine 4.5 mg/Day (Double-blind Treatment Period) | 0/56 (0%) | 1/54 (1.9%) | 3/54 (5.6%) |
| Placebo (Double-blind Safety Follow-up) | 0/54 (0%) | 0/53 (0%) | 0/53 (0%) |
| Cariprazine 3.0 mg/Day (Double-blind Safety Follow-up) | 0/49 (0%) | 0/49 (0%) | 1/49 (2%) |
| Cariprazine 4.5 mg/Day (Double-blind Safety Follow-up) | 0/56 (0%) | 2/54 (3.7%) | 0/54 (0%) |
| Event | Cariprazine 4.5 mg/Day (Open-label Treatment Period) | Cariprazine 4.5 mg/Day (Open-label Safety Follow-up) | Placebo (Double-blind Treatment Period) | Cariprazine 3.0 mg/Day (Double-blind Treatment Period) | Cariprazine 4.5 mg/Day (Double-blind Treatment Period) | Placebo (Double-blind Safety Follow-up) | Cariprazine 3.0 mg/Day (Double-blind Safety Follow-up) | Cariprazine 4.5 mg/Day (Double-blind Safety Follow-up) |
|---|---|---|---|---|---|---|---|---|
| SchizophreniaPsychiatric disorders | 4/587 | 2/273 | 4/53 | 0/49 | 0/54 | 0/53 | 0/49 | 1/54 |
| Cataract subcapsularEye disorders | 0/587 | 0/273 | 1/53 | 0/49 | 0/54 | 0/53 | 0/49 | 0/54 |
| Retinal detachmentEye disorders | 0/587 | 0/273 | 1/53 | 0/49 | 0/54 | 0/53 | 0/49 | 0/54 |
| Psychotic disorderPsychiatric disorders | 2/587 | 1/273 | 0/53 | 0/49 | 1/54 | 0/53 | 0/49 | 1/54 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 0/188 | 1/95 | 0/14 | 0/17 | 0/22 | 0/14 | 0/17 | 0/22 |
| Suicidal ideationPsychiatric disorders | 1/587 | 1/273 | 0/53 | 0/49 | 0/54 | 0/53 | 0/49 | 0/54 |
| Suicide attemptPsychiatric disorders | 1/587 | 1/273 | 0/53 | 0/49 | 0/54 | 0/53 | 0/49 | 0/54 |
| Food poisoningGastrointestinal disorders | 0/587 | 1/273 | 0/53 | 0/49 | 0/54 | 0/53 | 0/49 | 0/54 |
| Abscess limbInfections and infestations | 0/587 | 1/273 | 0/53 | 0/49 | 0/54 | 0/53 | 0/49 | 0/54 |
| DelusionPsychiatric disorders | 2/587 | 0/273 | 0/53 | 0/49 | 0/54 | 0/53 | 0/49 | 0/54 |
| Event | Cariprazine 4.5 mg/Day (Open-label Treatment Period) | Cariprazine 4.5 mg/Day (Open-label Safety Follow-up) | Placebo (Double-blind Treatment Period) | Cariprazine 3.0 mg/Day (Double-blind Treatment Period) | Cariprazine 4.5 mg/Day (Double-blind Treatment Period) | Placebo (Double-blind Safety Follow-up) | Cariprazine 3.0 mg/Day (Double-blind Safety Follow-up) | Cariprazine 4.5 mg/Day (Double-blind Safety Follow-up) |
|---|---|---|---|---|---|---|---|---|
| InsomniaPsychiatric disorders | 50/587 | 0/273 | 0/53 | 4/49 | 1/54 | 0/53 | 1/49 | 0/54 |
| HeadacheNervous system disorders | 38/587 | 0/273 | 0/53 | 0/49 | 0/54 | 0/53 | 0/49 | 0/54 |
| Cataract nuclearEye disorders | 0/587 | 0/273 | 2/53 | 3/49 | 1/54 | 0/53 | 0/49 | 0/54 |
| Ovarian cystReproductive system and breast disorders | 0/188 | 0/95 | 0/14 | 0/17 | 0/22 | 0/14 | 1/17 | 0/22 |
| DiarrhoeaGastrointestinal disorders | 0/587 | 0/273 | 3/53 | 2/49 | 1/54 | 0/53 | 0/49 | 0/54 |
Double-blind Safety Population included all participants who took at least 1 dose of cariprazine during and double-blind treatment period.
| Age, Continuous(years) | Placebo (Double-blind Treatment Period) | Cariprazine 3.0 mg/Day (Double-blind Treatment Period) | Cariprazine 4.5 mg/Day (Double-blind Treatment Period) | Total |
|---|---|---|---|---|
| Mean | 41.7 ± 10.94 | 40.6 ± 10.84 | 42.7 ± 11.08 | 41.7 ± 10.92 |
| Sex: Female, Male(Participants) | Placebo (Double-blind Treatment Period) | Cariprazine 3.0 mg/Day (Double-blind Treatment Period) | Cariprazine 4.5 mg/Day (Double-blind Treatment Period) | Total |
|---|---|---|---|---|
| Female | 14 | 17 | 22 | 53 |
| Male | 39 | 32 | 32 | 103 |
| Race (NIH/OMB)(Participants) | Placebo (Double-blind Treatment Period) | Cariprazine 3.0 mg/Day (Double-blind Treatment Period) | Cariprazine 4.5 mg/Day (Double-blind Treatment Period) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 | 2 |
| Asian | 0 | 0 | 2 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 34 | 38 | 39 | 111 |
| White | 17 | 11 | 11 | 39 |
| More than one race | 1 | 0 | 1 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo (Double-blind Treatment Period) | Cariprazine 3.0 mg/Day (Double-blind Treatment Period) | Cariprazine 4.5 mg/Day (Double-blind Treatment Period) | Total |
|---|---|---|---|---|
| Hispanic | 10 | 12 | 10 | 32 |
| Non-Hispanic | 43 | 37 | 44 | 124 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For details on when studies are available for sharing, please refer to the link below.
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.
Data sharing details ↗ · vivli.org
Ran from Jul 2018 to primary completion in Feb 2021, 30 months.
Results were first posted in Mar 2022, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cariprazine